November 2023
Kadans Science Partner given green light for new purpose-built laboratory scheme in King’s Cross, London
London, November 29, 2023 - Kadans Science Partner (“Kadans”) has secured planning permission from the London Borough of Islington, for a new, purpose-built laboratory and office building in London’s Knowledge Quarter, King’s Cross. The new build development has been designed with a specialist professional team and the Kadans Science Partner inhouse development team. This investment represents the physical implementation of Kadans’ long-term model to bolster both specialist…
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis
Refined focus on neurodegenerative disease targets
Proceeds to be used to advance lead programme targeting FAN1 nuclease in Huntington’s Disease towards the clinic
Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology…
Biocair, a leading specialist in cell and gene therapy logistics, is proud to announce its alliance with Pharma.Aero, a global cross-industry collaboration platform. Together, they are driving transformation in the cell and gene therapy (CGT) supply chain.
Cell and gene therapies are a revolutionary way to fight disease in that they offer patients complete personalization of medicine. These time-sensitive and life-changing medicines need logistics solutions as innovative as they are.
To ensure the supply chain is consistently improving, Pharma.Aero set up the Cell and Gene Therapies Project…
Source Genomics White Paper explores the transformative power of multi-omics in genomic research.
Multiomics combines the various ‘omics disciplines that make up the complex landscape of life science research. With the integration of genomic, transcriptomic, proteomic and epigenomic data, we obtain an advanced vision of the overarching framework behind all phenotypic outcomes.
This White Paper highlights the central role of multiomics in life science research, including its practical applications across diverse fields spanning cancer research, drug development and the ongoing journey…
AMSBIO has announced a new range of customizable ELISA assay kits designed to enable experienced researchers to achieve reliable and reproducible assay results.
With over 500 ELISA kits to choose from, the new range covers a wide variety of biological processes, targets, and sample types. Reagents such as matched antibody pairs and a micro-ELISA pre-plate have been carefully screened and validated to save you time and money.
By combining uncoated ELISA and Ancillary reagent kit with optimized and pre-titrated reagents, researchers can enhance the reliability of their ELISA assay development.…
Entire 11,000 sq ft next generation lab developed by Gen Two to become the British biotech company’s HQ
LONDON, 23 NOVEMBER 2023 – Constructive Bio
Constructive Bio, a visionary biotech company, is excited to announce their transformative growth and relocation to their new headquarters, 'The Recodery'. Since their establishment in 2022, backed by a £12.4 million seed investment, and under the leadership of their female CEO, Ola Wlodek, PhD EMBA and scientific guidance of professor Jason Chin as a CSO, the company now boasts a robust and growing team. Constructive Bio’s journey began in…
"AstraZeneca launches Evinova, a separate health-tech business to accelerate innovation across the life sciences sector and the delivery of clinical trials with the aim of improving the patient experience and the delivery of better health outcomes."
Exciting to see our Corporate Sponsor, AstraZeneca, is making significant advances and investment in transforming the healthcare industry through technology, enabling them to develop innovative solutions to improve the patient experience in clinical trials and accelerate the process of getting new treatments to patients. Continue…
Innovate UK, a division of UK Research and Innovation, is offering an investment opportunity of up to £10 million for pioneering projects in advancing cancer immunotherapies and pediatric cancer treatments.
Projects may focus on:
next generation immunotherapies and immunomodulatory drugs
manipulation of the tumour microenvironment to promote immune responses against solid tumours
novel therapeutics that consider the unique characteristics of paediatric or young people’s cancers
clinical decision support tools to optimise treatment selection and therapeutic dosing for children and young…
Arise Innovation Hubs, part of Anglia Ruskin University (ARU), has launched a new grant programme. Arise ABOVE (Arise Beyond Open Innovation for Value and Entrepreneurship) will deliver innovation grants, expert support and events to unlock HealthTech and MedTech investment in Essex.
Grant funds of up to £5,000 will be available to organisations based, or looking to grow, in Essex. Supported by the Arise entrepreneurial ecosystem, the programme will stimulate the Health Technology and MedTech sectors, generating increased research and development collaborations, investment and local…
OXFORD, UK – 22 November 2023 – PrecisionLife®, a leading computational biology company focused on precision medicine in complex chronic diseases, announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.
Gerald joins PrecisionLife as SVP Corporate Development working across both biopharma and healthcare. Gerald is a molecular biologist who received his PhD in Antimicrobial Drug Discovery under the Glaxo Scholarship Program. After several years…